Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston
3
×
boston blog main
boston top stories
clinical trials
life sciences
national blog main
allergan
crispr
cynthia collins
editas medicine
gene editing
san francisco blog main
abbvie
alzheimer's disease
astellas pharma
atlas venture
audentes therapeutics
avidity biosciences
bluebird bio
deals
drugs
duchenne muscular dystrophy
dyne therapeutics
facioscapulohumeral muscular dystrophy
gene therapy
joshua brumm
kaleido biosciences
katrine bosley
leber congenital amaurosis
leber congenital amaurosis type 10
michelle robertson
muscular dystrophy
myotonic dystrophy type 1
national top stories
new york blog main
parkinson's disease
rare disease drugs
rare diseases
romesh subramanian
What
experimental
3
×
editas
editing
gene
genetic
humans
medicines
abbvie
ago
allergan
alliance
biotech
biotechs
blessing
bosley
ceo
check
clinical
considering
crispr
cusp
data
depart
diseases
drug
dyne
early
exits
expected
eyes
having
ipo
ipos
katrine
long
medicine
million
muscle
pact
partner
Language
unset
Current search:
experimental
×
boston
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
5 years ago
Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial